Social Media Ideas for Amavex

Evaxion Presents New Preclinical Data for AI-Designed CMV Vaccine Program EVX-V1

New preclinical findings show AI-discovered T-cell epitopes may improve control of CMV infection.

AEVEX Corp. (AVEX) Q2 2026 Earnings Call Transcript

Vivex Biologics Launches VIA Linxâ„¢, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advan...

New molecular medical device joins Vivex's growing suite of allograft and advanced wound care technologies.

DataMeds AI's Corexa Pharmacy Launches Tollo Health's Tollovid(R) and Galactovid(TM)

Launch targets acute viral infection and Long COVID markets through www.CorexaRx.com/Store

Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win

Amylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes b...

BioXcel

BioXcel Anonymous (not verified) Sun, 08/30/2026 - 09:43 field_thread_url https://cafepharma.com/boards/threads/bioxcel.674502/ board na...

<![CDATA[FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia in Patients Aged 12 and Older]]>

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline...

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset

Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a rare autoimmune condition where Spero aims to offer advantages over...

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

INVIVYD

INVIVYD Anonymous (not verified) Tue, 08/04/2026 - 21:28 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...

Amylyx Plans FDA Filing After GLP-1 Drug Hits Trial Goals in Rare Metabolic Condition

Amylyx Pharmaceuticals’ avexitide led to statistically significant and clinically meaningful reductions in hypoglycemic events in patients with post-bariatric hypoglycemia (PBH). T...

<![CDATA[Osivax And GC Biopharma Enter Collaboration to Develop Next Generation Influenza Vaccine ]]>

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Affinity AI Launches B2B Marketplace for Compounded Peptides and GLP-1s

A new sourcing portal connects clinics with compounding pharmacies across peptides, GLP-1s, and other compounded therapeutics.

Vivid Dx Raises $15M | Mirae Launches with $5.4M

Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings. Vivid Dx Raises $15M to Hel...

Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch

<![CDATA[Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics for alvelestat ]]>

Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs

Vogenx’s mizagliflozin is heading into Phase 2b testing for post-bariatric hypoglycemia (PBH). Amylyx Pharmaceuticals and Recordati are developing injectable peptide drugs for this...

Exousia Bio Nearing Completion of Milestone Multimillion-Dollar Capital Investment

Strategic Financing to Accelerate Exosome Pipeline Expansion, International Joint Ventures, and Scale-Up of NexTel Medical (MAJI)

NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion An...

Company targets a growing $1.2B+ North American pet oncology market leveraging proprietary exosome-based diagnostic technologies.

<![CDATA[Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly]]>